CO7141411A2 - Formulaciones y métodos para la administración vaginal de antiprogestinas - Google Patents
Formulaciones y métodos para la administración vaginal de antiprogestinasInfo
- Publication number
- CO7141411A2 CO7141411A2 CO14259346A CO14259346A CO7141411A2 CO 7141411 A2 CO7141411 A2 CO 7141411A2 CO 14259346 A CO14259346 A CO 14259346A CO 14259346 A CO14259346 A CO 14259346A CO 7141411 A2 CO7141411 A2 CO 7141411A2
- Authority
- CO
- Colombia
- Prior art keywords
- vaginal administration
- antiprogestins
- methods
- formulations
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La materia objeto de la presente invención espertinente al campo de la administración vaginal de agentesfarmacéuticamente activos. Modalidades de la presenteinvención describen métodos para tratar una variedad detrastornos relacionados con progesterona por laadministración vaginal de una cápsula de pululano quecomprende una o más antiprogestinas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653674P | 2012-05-31 | 2012-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7141411A2 true CO7141411A2 (es) | 2014-12-12 |
Family
ID=48614182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14259346A CO7141411A2 (es) | 2012-05-31 | 2014-11-25 | Formulaciones y métodos para la administración vaginal de antiprogestinas |
Country Status (23)
Country | Link |
---|---|
US (1) | US10328022B2 (es) |
EP (1) | EP2854763B1 (es) |
JP (1) | JP6341910B2 (es) |
KR (1) | KR102127348B1 (es) |
CN (1) | CN104334158B (es) |
AU (1) | AU2013267359C1 (es) |
BR (1) | BR112014029131B1 (es) |
CA (1) | CA2872644A1 (es) |
CL (1) | CL2014003232A1 (es) |
CO (1) | CO7141411A2 (es) |
CR (1) | CR20140567A (es) |
EA (1) | EA030444B1 (es) |
ES (1) | ES2701400T3 (es) |
HK (1) | HK1206622A1 (es) |
IL (1) | IL235450B (es) |
IN (1) | IN2014DN10548A (es) |
MX (2) | MX363640B (es) |
NZ (1) | NZ702467A (es) |
PH (1) | PH12014502516B1 (es) |
SG (2) | SG10201704858PA (es) |
UA (1) | UA114106C2 (es) |
WO (1) | WO2013181449A1 (es) |
ZA (1) | ZA201408262B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CN106232107B (zh) * | 2014-05-05 | 2020-06-05 | 艾尔建制药国际有限公司 | 用于抗孕激素的阴道递送的制剂和方法 |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11623008B2 (en) * | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
AU2015336065A1 (en) * | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3025709B1 (en) | 2014-11-27 | 2020-09-30 | Capsugel Belgium NV | Dosage form articles for external mucosal applications |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
AU2018251256B2 (en) * | 2017-04-14 | 2023-10-05 | Capsugel Belgium Nv | Pullulan capsules |
CN110678555B (zh) | 2017-04-14 | 2023-10-13 | 比利时胶囊公司 | 制作普鲁兰的方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
EP0163696B1 (en) | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
WO1996023503A1 (de) | 1995-02-02 | 1996-08-08 | Schering Aktiengesellschaft | Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
ATE194358T1 (de) | 1996-05-01 | 2000-07-15 | Us Gov Health & Human Serv | 21-substituierte progesteron derivate als antigestagene |
WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
AU2001245849B2 (en) | 2000-03-17 | 2007-01-04 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
IN191020B (es) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
CZ299942B6 (cs) | 2000-10-18 | 2008-12-29 | Schering Aktiengesellschaft | Farmaceutické prostredky obsahující antiprogestinpro prevenci a lécení hormonálne závislých onemocnení |
WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
CA2457526A1 (en) | 2001-08-29 | 2003-03-13 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
JP2003143474A (ja) | 2001-11-02 | 2003-05-16 | Matsushita Electric Ind Co Ltd | 映像信号処理システム |
US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
US7833545B2 (en) | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
JP5017109B2 (ja) | 2004-07-09 | 2012-09-05 | ザ・ポピュレイション・カウンシル,インコーポレイテッド | プロゲステロン受容体モジュレーターを含有する徐放性組成物 |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
KR20070114187A (ko) | 2005-03-22 | 2007-11-29 | 레프로스 쎄라피우틱스 아이엔씨. | 트랜스-클로미펜의 투약 방법 |
JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
WO2007038796A1 (en) * | 2005-09-29 | 2007-04-05 | Repros Therapeutics Inc. | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
US8173626B2 (en) | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
KR20070116538A (ko) * | 2006-06-05 | 2007-12-10 | 유겐가이샤 코리츠 쇼지 | 삽입 보조 기구 |
JP2008012281A (ja) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | 挿入補助器具 |
CZ300424B6 (cs) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
HUE051484T2 (hu) | 2006-10-24 | 2021-03-01 | Allergan Pharmaceuticals Int Ltd | Készítmények és eljárások az endometriális proliferációk elnyomására |
WO2008124617A2 (en) * | 2007-04-05 | 2008-10-16 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
WO2008129396A2 (en) | 2007-04-20 | 2008-10-30 | Preglem S.A. | Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding |
DK2197415T3 (da) * | 2007-09-20 | 2014-05-26 | Lapidot Medical Imp And Marketing Ltd | Sammensætninger og midler til at behandle uterusleiomyomer, leiomyom, myom, uterusfibroid, endometriose, adenomyose og beslægtede forstyrrelser med mifepriston |
TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
CN103079632A (zh) | 2009-09-29 | 2013-05-01 | 梅迪梅特里科斯个性化药物传输私人有限公司 | 用于施用物质的子宫内电子胶囊 |
UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
WO2012121767A1 (en) | 2011-03-09 | 2012-09-13 | Arstat, Inc. | Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-05-30 CA CA2872644A patent/CA2872644A1/en not_active Abandoned
- 2013-05-30 JP JP2015515205A patent/JP6341910B2/ja not_active Expired - Fee Related
- 2013-05-30 WO PCT/US2013/043447 patent/WO2013181449A1/en active Application Filing
- 2013-05-30 MX MX2014014054A patent/MX363640B/es unknown
- 2013-05-30 BR BR112014029131-4A patent/BR112014029131B1/pt not_active IP Right Cessation
- 2013-05-30 UA UAA201414106A patent/UA114106C2/uk unknown
- 2013-05-30 SG SG10201704858PA patent/SG10201704858PA/en unknown
- 2013-05-30 NZ NZ702467A patent/NZ702467A/en not_active IP Right Cessation
- 2013-05-30 EA EA201492290A patent/EA030444B1/ru unknown
- 2013-05-30 AU AU2013267359A patent/AU2013267359C1/en not_active Ceased
- 2013-05-30 ES ES13728632T patent/ES2701400T3/es active Active
- 2013-05-30 US US14/403,141 patent/US10328022B2/en not_active Expired - Fee Related
- 2013-05-30 SG SG11201407397WA patent/SG11201407397WA/en unknown
- 2013-05-30 EP EP13728632.4A patent/EP2854763B1/en active Active
- 2013-05-30 KR KR1020147032210A patent/KR102127348B1/ko active IP Right Grant
- 2013-05-30 CN CN201380028413.4A patent/CN104334158B/zh not_active Expired - Fee Related
- 2013-05-30 IN IN10548DEN2014 patent/IN2014DN10548A/en unknown
-
2014
- 2014-11-02 IL IL235450A patent/IL235450B/en active IP Right Grant
- 2014-11-11 ZA ZA2014/08262A patent/ZA201408262B/en unknown
- 2014-11-11 PH PH12014502516A patent/PH12014502516B1/en unknown
- 2014-11-19 MX MX2019003467A patent/MX2019003467A/es unknown
- 2014-11-25 CO CO14259346A patent/CO7141411A2/es unknown
- 2014-11-27 CL CL2014003232A patent/CL2014003232A1/es unknown
- 2014-12-09 CR CR20140567A patent/CR20140567A/es unknown
-
2015
- 2015-07-30 HK HK15107275.4A patent/HK1206622A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7141411A2 (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
GEP20207102B (en) | Sulfonamides as modulators of sodium channels | |
EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
UY33277A (es) | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso | |
CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
EP2985029A4 (en) | MEDICATION FOR EXTERNAL USE IN CLEANING AND CARE OF OVARIES, VAGS AND VULVES | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
HK1201189A1 (en) | Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections | |
EA201591603A1 (ru) | Новые терапевтические комбинации миртазапина для применения при болевых расстройствах | |
MX2016002502A (es) | Composiciones farmaceuticas de bendamustina. | |
MX2014014258A (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis. | |
TH158984A (th) | สารประกอบที่ออกฤทธิ์ในการรักษาและวิธีการใช้ของสารประกอบดังกล่าว | |
MX2015013279A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. |